SciFluor Life Sciences develops fluorination technologies that improve drug properties such as metabolic stability and potency.
SciFluor Life Sciences is an Allied Minds funded company with a late-stage fluorination technology that improves drug properties such as metabolic stability, potency, bioavailability, and blood-brain-barrier penetration. The company's late-stage fluorination technology is licensed exclusively from Harvard University. SciFluor's technology enables end-stage or any-stage fluorination of a wide variety of organic compounds.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Apr 21, 2015 | Series B | $30M | 1 | — | — | Detail |